Glatiramer Acetate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB05259 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hemoglobinopathy | KG + DL |
| 2 | plasma cell myeloma | KG + DL |
| 3 | female breast carcinoma | KG + DL |
| 4 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 5 | beta-thalassemia with other manifestations | KG + DL |
| 6 | indolent plasma cell myeloma | KG + DL |
| 7 | gastric linitis plastica | KG + DL |
| 8 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 9 | pyropoikilocytosis, hereditary | KG + DL |
| 10 | pyruvate kinase deficiency of red cells | KG + DL |
| 11 | hereditary persistence of fetal hemoglobin-sickle cell disease syndrome | KG + DL |
| 12 | sickle cell-beta-thalassemia disease syndrome | KG + DL |
| 13 | sickle cell-hemoglobin c disease syndrome | KG + DL |
| 14 | sickle cell-hemoglobin d disease syndrome | KG + DL |
| 15 | sickle cell-hemoglobin E disease syndrome | KG + DL |
| 16 | gastric carcinoma | KG + DL |
| 17 | diffuse gastric adenocarcinoma | KG + DL |
| 18 | hereditary breast ovarian cancer syndrome | KG + DL |
| 19 | hyperthyroidism | KG + DL |
| 20 | acrocephalopolydactyly | KG + DL |
| 21 | unclassified myelodysplastic syndrome | KG + DL |
| 22 | myelodysplastic syndrome | KG + DL |
| 23 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 24 | refractory cytopenia of childhood | KG + DL |
| 25 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | KG + DL |
| 26 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 27 | aregenerative anemia | KG + DL |
| 28 | severe early-onset pulmonary alveolar proteinosis due to MARS deficiency | KG + DL |
| 29 | medullary cystic kidney disease | KG + DL |
| 30 | gastric neoplasm | KG + DL |
| 31 | gastric cancer | KG + DL |
| 32 | myocardial infarction (disease) | KG + DL |
| 33 | short stature-optic atrophy-Pelger-HuC+t anomaly syndrome | KG + DL |
| 34 | Epstein-Barr virus-associated carcinoma | KG + DL |
| 35 | gastric adenocarcinoma and proximal polyposis of the stomach | KG + DL |
| 36 | rheumatoid arthritis | KG + DL |
| 37 | carcinoma in situ of gastric body | KG + DL |
| 38 | carcinoma in situ of gastric cardia | KG + DL |
| 39 | neutrophil immunodeficiency syndrome | KG + DL |
| 40 | retrograde amnesia | KG + DL |
| 41 | gastric cardia adenocarcinoma | KG + DL |
| 42 | Hennekam lymphangiectasia-lymphedema syndrome | KG + DL |
| 43 | malignant gastric germ cell tumor | KG + DL |
| 44 | Dengue hemorrhagic fever | KG + DL |
| 45 | signet ring cell gastric adenocarcinoma | KG + DL |
| 46 | microinvasive gastric cancer | KG + DL |
| 47 | gastric tubular adenocarcinoma | KG + DL |
| 48 | lymphosarcoma | KG + DL |
| 49 | malignant gastric granular cell tumor | KG + DL |
| 50 | congenital deficiency in alpha-fetoprotein | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.